Medtronic's PAD tech beats angioplasty; Vital Therapies dials down its IPO plan;

@FierceMedDev: CyVek immunoassay technology gets $10M investment. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: After a successful IPO, LDR looks to raise more cash. News | Follow @VarunSaxena2

@EmilyWFierce: Motorized, sensor-driven wheelchair could provide a new level of mobility for those with severe disabilities. Article | Follow @EmilyWFierce

@MichaelGFierce: DNA nanorobot delivers drugs through flap that opens and closes. More from FierceDrugDelivery | Follow @MichaelGFierce

> Medtronic's ($MDT) IN.PACT Admiral drug-coated balloon beat out standard angioplasty in treating peripheral artery disease, the company said. News

> CardioKinetix's implanted ventricular device performed well in 12-month results, the company said, improving heart function, 6-minute walk test performance and rates of hospitalization. More

> Artificial liver outfit Vital Therapies has reduced its expected range in a second attempt at going public, eyeing $63 million at between $13 and $15 per share. Item

Biotech News

@FierceBiotech: Little Deciphera raises its cancer R&D flag in Boston's bustling biotech hub. More | Follow @FierceBiotech

@JohnCFierce: Agios shares spike on enthusiastic response to small, early-stage leukemia study. Story | Follow @JohnCFierce

@DamianFierce: Here's FierceBiotech's look at every drug developer IPO from the first quarter. Report | Follow @DamianFierce

@EmilyMFierce: 40% of the world's population is at risk from dengue. More in WHO's report for World Health Day. Report | Follow @EmilyMFierce

> Roche's pRED jumps into epigenetics with $521M-plus cancer drug deal. Article

> Sanofi decides to take a second shot on Lemtrada app. More

> Pfizer's flagship palbociclib stymies cancer progression but falls short on survival. News

Pharma News

@FiercePharma: Top-read story this weekend: Novartis fighting two-pronged legal battle in India on Galvus patent. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. Article | Follow @TracyStaton

@EricPFierce: Daiichi Sankyo hinted months ago it was tired of Ranbaxy's issues. Buyout means Sun Pharma takes them on. More | Follow @EricPFierce

@CarlyHFierce: Novartis meningitis B vaccine Bexsero receives FDA breakthrough therapy designation in the U.S. Release | Follow @CarlyHFierce

> GlaxoSmithKline confronts new bribery allegations, this time in Iraq. News

> Sanofi misled investors with rosy Lemtrada predictions, lawsuit alleges. More

> Mallinckrodt bets $5.6B on Questcor and its controversial Acthar drug. Story

CRO News

> Clinipace signs up to get a brain-stimulating device on the U.S. market. Article

> WuXi bets on anti-counterfeiting tech with an eye on drug safety. More

> Actavis picks Particle Sciences for generics development. Story

> AMRI expects its $41M Cedarburg deal to pay off right away. News

> Evotec lands two more deals to share risks and rewards of R&D. Report

> Charles River wraps up $179M deal for Galapagos' CRO biz. Item

Biotech IT News

> Merck KGaA and Pfizer tap into Broad Institute's data skills for lupus project. Story

> Tufts survey shows social media still on fringes of clinical trials. More

> Billionaire-backed startup puts Big Data, AI at the heart of drug discovery. News

> Merck vaccine plant taps R&D's Big Data platform to solve yield conundrum. Article

> IMS Health stock jumps after second biggest U.S. IPO of 2014. Item

> Europe to create public clinical trial results database after passing law. Report

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.